Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 37 references it cites were found in a registry or an index; 39 of the 54 sources its claims cite were checked for support.

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Open access

Abstract

KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRA S G12C -positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS–MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC. Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients with KRA S G12C -positive CRC ( n = 29) from arm C of an ongoing phase 1b trial. The primary objective was to evaluate safety. Secondary objectives included preliminary antitumor activity. The safety profile of this combination was consistent with those of single-agent divarasib and cetuximab. Treatment-related adverse events led to divarasib dose reductions in four patients (13.8%); there were no treatment withdrawals. The objective response rate was 62.5% (95% confidence interval: 40.6%, 81.2%) in KRAS G12C inhibitor-naive patients ( n = 24). The median duration of response was 6.9 months. The median progression-free survival was 8.1 months (95% confidence interval: 5.5, 12.3). As an exploratory objective, we observed a decline in KRA S G12C variant allele frequency associated with response and identified acquired genomic alterations at disease progression that may be associated with resistance. The manageable safety profile and encouraging antitumor activity of divarasib plus cetuximab support the further investigation of this combination in KRA S G12C -positive CRC. ClinicalTrials.gov identifier: NCT04449874

Overview

CoChat Summary

TL;DR

In arm C of a phase 1b trial, divarasib plus cetuximab was tolerable and showed encouraging activity in KRAS G12C-positive colorectal cancer. Among KRAS G12C inhibitor-naive patients, confirmed ORR was 62.5% and median PFS was 8.1 months.

Key findings

  • Safety: no dose-limiting toxicities were reported; all 29 patients had at least one treatment-related adverse event (TRAE), mostly grade 1–2 (91.6%). Grade 3 TRAEs occurred in 37.9%, grade 4 in 6.9%, and no grade 5 TRAEs occurred. TRAEs led to divarasib dose reductions in 13.8% and no divarasib withdrawals.
  • Antitumor activity: among 24 KRAS G12C inhibitor-naive patients, confirmed ORR was 62.5% (95% CI: 40.6%, 81.2%), with 1 complete response, 15 partial responses, and 8 stable disease. Median duration of response was 6.9 months and median PFS was 8.1 months (95% CI: 5.5, 12.3). Among 5 patients with prior KRAS G12C inhibitor treatment, 3 (60.0%) had a partial response.
  • Biomarker analysis: KRAS G12C variant allele frequency declined with response or stable disease; at C3D1, VAF was <0.5% in 17 of 22 evaluated patients (77.3%). At end of treatment, 13 of 14 profiled patients (92.9%) had at least one acquired genomic alteration that may be associated with resistance.

Methods

  • Phase 1b, open-label, multicenter dose-escalation and dose-expansion study; arm C enrolled 29 patients with advanced or metastatic KRAS G12C-positive colorectal cancer from 17 sites in 10 countries between 28 July 2021 and 07 October 2022.
  • Patients received oral divarasib 200 mg (n = 3) or 400 mg (n = 26) once daily plus intravenous cetuximab (400 mg/m² on C1D1, then 250 mg/m² once weekly) in 21-day cycles.
  • Safety was assessed in all treated patients; preliminary antitumor activity was investigator-assessed per RECIST v1.1, with confirmed ORR summarized using Clopper–Pearson 95% CIs and time-to-event endpoints summarized by Kaplan–Meier. Exploratory ctDNA profiling was performed on longitudinal plasma samples.

Limitations

  • Stated: the study was limited by the small number of patients enrolled into this arm and the lack of comparison of divarasib plus cetuximab to a standard-of-care treatment in KRAS G12C-positive colorectal cancer; cross-trial comparisons are difficult due to differences in patient populations.
  • Evident: this is a single-arm, nonrandomized trial without a control group. Activity outcomes are reported for the KRAS G12C inhibitor-naive subset (n = 24), while safety includes all 29 patients.
  • Evident: biomarker analyses of response and acquired resistance were exploratory and retrospective, with resistance profiling based on 14 patients who had end-of-treatment samples.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02696-8

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Patient disposition. Patient disposition for all 29 patients that were enrolled and received divarasib plus cetuximab.
Fig. 1 Patient disposition. Patient disposition for all 29 patients that were enrolled and received divarasib plus cetuximab.CC BY · PubMed Central
Fig. 2 Antitumor activity for all patients. a, Waterfall plot showing the best percentage decrease from baseline in the tumor burden (defined as the sum of the longest diameters of all target lesions) in all 29 patients. b, Swimmer plot showing the time on study treatment, best response, and reason for treatment discontinuation for all 29 patients. c, Spider plot of the percentage changes from baseline in sum of tumor diameters over time in all 29 patients.
Fig. 2 Antitumor activity for all patients. a, Waterfall plot showing the best percentage decrease from baseline in the tumor burden (defined as the sum of the longest diameters of all target lesions) in all 29 patients. b, Swimmer plot showing the time on study treatment, best response, and reason for treatment discontinuation for all 29 patients. c, Spider plot of the percentage changes from baseline in sum of tumor diameters over time in all 29 patients.CC BY · PubMed Central
Fig. 3 Duration of response and PFS for KRAS G12C inhibitor-naive patients. a, Kaplan–Meier plot for duration of response for the 16 KRAS G12C inhibitor-naive patients who experienced a CR or PR. b, Kaplan–Meier plot for median PFS for all 24 KRAS G12C inhibitor-naive patients.
Fig. 3 Duration of response and PFS for KRAS G12C inhibitor-naive patients. a, Kaplan–Meier plot for duration of response for the 16 KRAS G12C inhibitor-naive patients who experienced a CR or PR. b, Kaplan–Meier plot for median PFS for all 24 KRAS G12C inhibitor-naive patients.CC BY · PubMed Central
Fig. 4 Biomarker analysis of ctDNA. a, Shown is the KRAS G12C VAF at baseline (C1D1) and early treatment time points (C1D15, C3D1) among patients with a detectable KRAS G12C mutation from cfDNA at C1D1 (n = 20 shown, each line represents one patient). Two patients with missing C1D15 plasma samples are not shown in the plot. Box-and-whisker plots at each time point in each indication show the median (center line) with the minima and maxima box boundaries representing the 25th and 75th percentiles; whiskers represent the minimum and maximum values of the data that are within 1.5 times the interquartile range under the 25th and over the 75th percentiles. b, Shown are putative genetic mechanisms of acquired resistance to divarasib plus cetuximab combination treatment among 14 patients who had an EoT visit before 01 May 2023. Each row represents one patient with the first four columns describing assigned divarasib dose, best response, PFS, prior KRAS G12C inhibitor use and subsequent columns indicating acquired genomic alterations at EoT.
Fig. 4 Biomarker analysis of ctDNA. a, Shown is the KRAS G12C VAF at baseline (C1D1) and early treatment time points (C1D15, C3D1) among patients with a detectable KRAS G12C mutation from cfDNA at C1D1 (n = 20 shown, each line represents one patient). Two patients with missing C1D15 plasma samples are not shown in the plot. Box-and-whisker plots at each time point in each indication show the median (center line) with the minima and maxima box boundaries representing the 25th and 75th percentiles; whiskers represent the minimum and maximum values of the data that are within 1.5 times the interquartile range under the 25th and over the 75th percentiles. b, Shown are putative genetic mechanisms of acquired resistance to divarasib plus cetuximab combination treatment among 14 patients who had an EoT visit before 01 May 2023. Each row represents one patient with the first four columns describing assigned divarasib dose, best response, PFS, prior KRAS G12C inhibitor use and subsequent columns indicating acquired genomic alterations at EoT.CC BY · PubMed Central
Extended Data Fig. 1 Mean (SD) Plasma Concentration-Time Profiles of Divarasib as a Single Agent and in Combination with Cetuximab Following Multiple Doses. Multiple-dose pharmacokinetic profile of divarasib was obtained on either C1D8 or C2D1 from blood samples collected over an 8 hour period following administration of divarasib 400 mg QD (n = 76 patients)1 or divarasib 400 mg QD plus 250 mg/m2 of cetuximab QW (n = 21 patients). Time (hr) is shown as nominal time and the error bars represent standard deviation around the mean divarasib plasma concentration (ng/mL) measured at each time point during the 8 hour post-dose interval.
Extended Data Fig. 1 Mean (SD) Plasma Concentration-Time Profiles of Divarasib as a Single Agent and in Combination with Cetuximab Following Multiple Doses. Multiple-dose pharmacokinetic profile of divarasib was obtained on either C1D8 or C2D1 from blood samples collected over an 8 hour period following administration of divarasib 400 mg QD (n = 76 patients)1 or divarasib 400 mg QD plus 250 mg/m2 of cetuximab QW (n = 21 patients). Time (hr) is shown as nominal time and the error bars represent standard deviation around the mean divarasib plasma concentration (ng/mL) measured at each time point during the 8 hour post-dose interval.CC BY · PubMed Central

Verification

Claims the paper makes

20 Valid · 0 Not valid · 4 Not checked · 43 Own results and interpretations

39 more claims · 6 with their cited sources checked

Create a free account to see all 67 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 14
  • Probably not a substantial claim. 9
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. Henry, J. T. et al. Comprehensive clinical and molecular characterization of KRASG12C-mutant colorectal cancer. JCO Precis. Oncol. 5, PO.20.00256 (2021).

Cited by

See all 144

Metadata

Authors
Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., Guren, T., Massarelli, E., Miller, W. H., Paz-Ares, L., Prenen, H., Amatu, A., Cremolini, C., Kim, T. W., Moreno, V., Ou, S.-H. I., Passardi, A., Sacher, A., Santoro, A., Stec, R., Ulahannan, S., Arbour, K., Lorusso, P., Luo, J., Patel, M. R., Choi, Y., Shi, Z., Mandlekar, S., Lin, M. T., Royer-Joo, S., Chang, J., Jun, T., Dharia, N. V., Schutzman, J. L., GO42144 Investigator and Study Group, & Han, S.-W.
Affiliations
  • The University of Melbourne (AU)
  • Seoul National University Bundang Hospital (KR)
  • Abramson Cancer Center (US)
  • Instituto de Investigación Biomédica de Málaga (ES)
  • UNSW Sydney (AU)
  • University Medical Center Utrecht (NL)
  • Oslo University Hospital (NO)
  • City Of Hope National Medical Center (US)
  • Jewish General Hospital (CA)
  • Universidad Complutense de Madrid (ES)
  • Antwerp University Hospital (BE)
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • University of Pisa (IT)
  • Asan Medical Center (KR)
  • University of California, Irvine (US)
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
  • University Health Network (CA)
  • Humanitas University (IT)
  • Sarah Cannon (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Yale Cancer Center (US)
  • Harvard University (US)
  • Genentech (US)
  • Seoul National University Hospital (KR)
Corresponding author
  • Desai, Jayesh
  • Han, Sae-Won
Venue
Nature Medicine
Published
2023-12-05
Volume
30
Issue
1
Pages
271-278
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4389338940
Cited by
144
References
37
Citations by year
2026: 42 · 2025: 62 · 2024: 40
FWCI
18.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
Genentech
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
divarasib, cetuximab, KRAS G12C mutation, colorectal cancer, KRAS G12C inhibitors, EGFR inhibitors, combination therapy, RAS/MAPK pathway, acquired resistance, variant allele frequency, treatment safety, anticancer activity
MeSH terms
Cetuximab, Progression-Free Survival, Humans, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. https://app.cochat.ai/papers/10.1038/s41591-023-02696-8
The paper
Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., Guren, T., Massarelli, E., Miller, W. H., Paz-Ares, L., Prenen, H., Amatu, A., Cremolini, C., Kim, T. W., Moreno, V., . . . Han, S.-W. (2024). Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02696-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.